Cells are injected directly into the damaged joint.
We treat knees, hips, shoulders, ankles, feet, elbows, wrists and hands, the spine, the sacroiliac joints, and the jaw. A typical large joint receives 20 to 60 million mesenchymal stem cells, placed inside the joint capsule under ultrasound or fluoroscopic guidance to calm inflammation and support cartilage, tendon, and bone.
The procedure takes 30 to 45 minutes, requires no general anesthesia, and you walk out of the clinic the same day.
Find your treatment area
Hover or tap a region to see what we treat there.
- KneeOsteoarthritis · Meniscus · Tendinopathy
- HipOsteoarthritis · Avascular necrosis · Labrum
- ShoulderRotator cuff · Osteoarthritis · AC joint
- SpineDisc · Facet joints · Radiculopathy
- SacroiliacSI dysfunction · Post-fusion pain
- AnkleOsteoarthritis · OCD lesions · Instability
- FootHallux rigidus · Plantar fasciitis
- ElbowTennis & golfer's elbow · UCL
- Wrist & HandThumb CMC · Small-joint OA · Tendons
- Jaw (TMJ)Jaw OA · Disc displacement
We treat ten regions of the body.
The conditions we treat in each region, and every protocol we run for it. Your physician sets the final prescription after reviewing your imaging.
No match for that term. Try the body area instead, or ask a physician directly — this list covers the most common indications, not every one.
Doses run from 20 to 100 million cells.
Every dose is expanded from Wharton's jelly umbilical-cord tissue, tested for viability, and scaled to the joint and the severity of disease.
20–60M
cells for a large joint — knee, hip, shoulder — placed directly into the joint capsule under image guidance.
100M
cells for the hardest problems: avascular necrosis of the hip and complex multi-level spine protocols.
ISO‑certified
GMP laboratory. Each dose is released only after sterility, identity, and viability verification.
What happens inside the joint.
Tap a step to follow the cells into the joint space.
Cross-section of a knee. The same principle applies at every joint we treat.
What recovery looks like.
A typical large-joint timeline. Your physician tailors it to your joint and your case.
Day 0
Same-day procedure
30–45 minutes, image-guided, no general anesthesia. You walk out of the clinic.
48–72 hours
Light activity
Walking unrestricted. Running and impact loading deferred to week four.
Weeks 4–6
Initial response
Most patients notice the first change here. Aftercare check-ins at 2, 6, and 12 weeks.
Months 3–6
Peak benefit
The repair biology matures. Trial data show benefits sustained at 12 months for many patients.
The evidence, briefly.
Three anchor findings from the peer-reviewed orthopedic literature.
RCT
Allogeneic MSCs beat hyaluronic acid on pain and function at 12 months in knee OA.
Vega A, et al. Transplantation, 2015.
UC‑MSC
Repeated umbilical-cord MSC dosing outperformed single dose and hyaluronic acid on WOMAC scores.
Matas J, et al. Stem Cells Transl Med, 2019.
Review
Systematic review: clinically relevant improvement with a favorable short-term safety profile.
Pas HI, et al. Br J Sports Med, 2017.
The evidence is encouraging and growing, but stronger for some joints than others, and none of it guarantees a result for any individual. Regenerative therapy complements orthopedic surgical care rather than replacing it — end-stage bone-on-bone disease is usually still a surgical problem. Not FDA-approved for these uses; provided in México under COFEPRIS after individual physician review of your imaging and history.
